Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Miata short presentation


Published on

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

Miata short presentation

  1. 1. The Minimal Information About T cell Assays (MIATA) project has two main goals that will be addressed in a two-step approach: Mid-term goal of MIATA = Phase 1: Establishment of a minimal information reporting framework for human T cell immune monitoring methods in scientific publications. Long-term goal of MIATA = Phase 2: Based on its successful implementation and substantiated feasibility and usefulness for scientific publications, adapt the reporting framework for annotations of immune monitoring data sets from human studies for a central database, possibly in the context of a Human Immunity Project. This will have to include structured database vocabulary. MIATA – Scope of Guidelines Dedicated Website:
  2. 2. MIATA – Level of Implementation (Phase 1) • MIATA is still in the preparatory phase (not finalized) • Several Journal editors have been approached and have expressed great interest • The core team expects that the final MIATA Guidelines will be published in Q4/2011 • For phase 1 supporting software or a CV/ontology are not needed • Public Consultation Period • Consensus Workshop • Webinars Guidelines Version 0.0 Guidelines Version 1.0 Guidelines Version 2.0 • Public Consultation Period • Consensus Workshop planed for June 2011 Level of Acceptance • Published at website • Announced in Immunity (2009, Vol. 31, p527) Publication of Guidelines only after broad acceptance has been achieved • Available at website • Workshop Results published in CII (2010 / PMID: 21080166)
  3. 3. MIATA – Status, Contributors, Funding Status: Project is still in a „long“ preparatory phase. A finalized and well-vetted version of the guideline for reporting in scientific publications should be available by end of 2011 Contributors: • Core Team (n=15) • Invited experts (n=25) • Comments from public consultation period (n=80) Funding: Te project has been supported by the Cancer Research Institute‘s Cancer Immunotherapy Consortium (CRI/CIC) and by the association for Cancer Immunotherapy‘s working group Cancer Immunotherapy Immunoguiding Program (CIMT/CIP) Final Consensus Workshop scheduled for June 2011 – FOCIS 2011